ClinicaliQ Trial Snapshot
- Study of E7386 in Participants With Selected Advanced Neoplasms — Active Not Recruiting • Phase I • NCT03264664.
- A study testing an oral cancer drug (E7386) to find safe doses and assess side effects in patients with advanced cancers.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will be conducted to assess the safety/tolerability profile of E7386 as a single agent administered orally in participants with selected advanced or recurrent neoplasms and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of E7386. Conditions: Advanced Neoplasms Interventions: E7386 Lead Sponsor: Eisai Inc. Planned Enrollment: 60 participants